Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 10,798

Document Document Title
WO/2019/010201A1
In one embodiment, the invention' provides a chimeric antigen receptor (CAR) T cell which is conjugated to a bi-functional molecule which is specific for both an extracellular binding domain of the chimeric antigen receptor (CAR) T cell ...  
WO/2019/006750A1
A reactive ultraviolet absorber applicable to polyurethane, and in particular, a compound as represented by a chemical formula (1), wherein R1 is H or Cl.  
WO/2019/002971A1
Described are high energy light blocking compounds and ophthalmic devices containing the compounds. In particular, described are hydroxybiphenyl benzotriazole structures with polymerizable functionality that block high energy light and a...  
WO/2019/001325A1
The present invention relates to a new crystal form of lesinurad, a preparation method therefor, a pharmaceutical composition containing the crystal form, and use of the crystal form in the preparation of a uric acid transporter inhibito...  
WO/2018/236115A1
The present invention relates to an 18F-labelled compound, and a use thereof. The compound selectively binds to a prostate-specific membrane antigen (PSMA), and enables the acquisition of clear prostate cancer images in a short time when...  
WO/2018/230528A1
Provided are a novel nitrocatechol derivative having COMT inhibitory effect and DDC inhibitory effect or a salt thereof and a medicinal composition comprising the same. A compound represented by general formula (1) or a pharmaceutically ...  
WO/2018/229027A1
The present invention relates to a process for the preparation of the compounds of formula (II) using a lanthanoid salt.  
WO/2018/224455A1
The invention relates to cyclopropyl compounds of formula (I), wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their use fo...  
WO/2018/219935A1
The invention relates to benzamides of formula (I), wherein Q is Q1 or Q2 or Q3 or Q4 (formulae (Q1), (Q2), (Q3), (Q4)); and their use as herbicides. In said formula (I), R2 is R2cR2dNC(O)NR2n-Z2, both R4 and R5 are hydrogen, R1, R3 and ...  
WO/2018/219936A1
The invention relates to benzamides of formula (I), wherein Q is Q1 or Q2 or Q3 or Q4, and their use as herbicides. In said formula (I), R2 is R2cR2dNC(O)NR2n-Z2, R5 is hydrogen, R1, R3, R4 and R6 represent groups such as hydrogen, halog...  
WO/2018/215818A1
The present invention relates to compounds of formula (I): wherein Q is O or S; R1 is a cyclic group substituted with at least one group X, wherein R1 may optionally be further substituted; X is any group comprising a carbonyl group; and...  
WO/2018/216823A1
Provided are novel compounds represented by the following general formula [1] or pharmaceutically acceptable salts thereof, that inhibit LpxC, as well as pharmaceutical drugs comprising those compounds or pharmaceutically acceptable salt...  
WO/2018/218093A1
The present invention provides a bioconjugation method and compounds for use therein. The bioconjugation method comprises the step of conjugating a biological molecule containing a first unsaturated functional group with a payload compri...  
WO/2018/211532A1
The present invention provides novel solid state forms of 2-((5-bromo-4-(4- cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)aceti c acid of formula (I) namely crystalline Form-M, crystalline Form-S, crystalline Form-N, crystalline...  
WO/2018/210354A1
A novel preparation method for the anti-gout drug lesinurad, and a key intermediate thereof. The method comprises the following reaction steps: 1) the compound of formula II undergoing a substitution reaction with R3-SH in the presence o...  
WO/2018/202689A1
The present invention relates to a process for the preparation of particular 2-(2H-[1,2,3]triazol-2-yl)-benzoic acid derivatives of formula (I), to certain crystalline forms of potassium salts of said 2-(2H-[1,2,3]triazol-2-yl)-benzoic a...  
WO/2018/199562A1
The present invention relates to a 2-amino-2-(1-(2-(2-hydroxyethoxy)ethyl)-1H-1,2,3-triazole-4- yl)propane-1,3-diol derivative which is a novel compound represented by chemical formula 1, and a use thereof. The novel compound of chemical...  
WO/2018/193385A1
The present invention relates to 4-substituted phenylamidine derivatives of the general formula (I), wherein R5-R6, ArA4, D, G, B, Q and an integer m have the meanings as defined in the description. The invention further relates to metho...  
WO/2018/190281A1
Provided are benzotriazole derivative compounds of the general formula that are novel compounds capable of strongly absorbing light in the ultraviolet range, particularly 300-330 nm, while strongly absorbing light in the visible light sh...  
WO/2018/191707A3
Provided herein, are compositions and methods of treatment for neurodegenerative diseases, such as neurodegenerative diseases associated with aging and methods for increasing longevity by inhibiting the expression of the protein exportin...  
WO/2018/189340A1
The present invention relates to novel benzohydroxamic compounds of formula (I) and (II) and pharmaceutically acceptable salts, isomers and prodrugs thereof, exhibiting a high selective inhibitory activity against histone deacetylase 6 (...  
WO/2018/187480A1
The present invention is directed to, in part, fused heteroaryl compounds and compositions useful for preventing and/or treating a disease or condition relating to aberrant function of a voltage-gated, sodium ion channel, for example, ab...  
WO/2018/184579A1
The present invention provides a triazole compound and use thereof in agriculture. In particularly, the present invention provides a triazole compound having Formula (A) and a preparation method thereof, a composition and formulation con...  
WO/2018/186365A1
The present invention relates to a novel read-through inducing agent, and also relates to a compound represented by general formula (I) (symbols in the formula are as described in the specification) or a pharmaceutically accepted salt th...  
WO/2018/178384A1
The invention relates to a compound of formula (I): A-B-D-E (I) or a pharmaceutically acceptable salt, solvate or polymorph thereof, including all tautomers and stereoisomers thereof, wherein: A is selected from monocyclic and bicyclic h...  
WO/2018/176202A1
The invention provides a method for preparing an additive represented by formula (I) used in polymers. The method includes the following steps: (a) adding phosphorus tribromide to a compound of formula (II) in the presence of a solvent c...  
WO/2018/180632A1
The present invention provides a benzotriazole derivative compound represented by a general formula (wherein R3 represents an alkyl group, and R4 represents an acryloyloxyalkyl group or a methacryloyloxyalkyl group), as a novel compound ...  
WO/2018/170306A1
The disclosure features novel lipids and compositions involving the same. Nanoparticle compositions include a novel lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Nanoparticle compositions fu...  
WO/2018/162806A1
The present invention relates to a compound of formula (I): (I) as defined in the description. The present invention also relates to a method for extracting biological membrane-associated membrane proteins, comprising a step of bringing ...  
WO/2018/159835A1
The present invention provides a strigolactone receptor inhibitor for plants, which contains, as effective component, at least one triazole urea compound represented by formula (I); an agricultural composition; a method for using this ag...  
WO/2018/151678A1
The present invention relates to heterocyclic compounds having the general Formula (I) wherein W1, W2, W3, W4, W7, W8, R1, R2, R3, R4, X2, X3, X4, Z1, Z2, Z3, Q, n and m are as defined herein, or a pharmaceutically acceptable salt thereo...  
WO/2018/150335A1
The present invention relates to novel co-crystals of lesinurad with nicotinamide, urea, and caffeine; methods for their preparation, pharmaceutical compositions and method of use thereof.  
WO/2018/129552A1
The present disclosure is directed to compounds and methods for the treatment of disorders associated with fluid retention or salt overload, such as heart failure (in particular, congestive heart failure), chronic kidney disease, end-sta...  
WO/2018/122325A1
The present invention pertains to a system of collaborative modifiers that are assembled into a multi molecule complex in vivo within a cell using bioorthogonal chemical reactions. The system of the invention is composed of multiple bind...  
WO/2018/124172A1
A method is provided by which an alcohol compound having a satisfactory purity is obtained from an ester compound in a simple manner. A high-purity alcohol compound can be obtained by: passing a solution which contains both an ester comp...  
WO/2018/121560A1
The present invention relates to a urea compound and a preparation method and an application thereof. The structure of the present compound is represented by formula (I), the definition of each variable in the formula being as described ...  
WO/2018/117063A1
[Problem] To provide a medicine, in particular, a medicine that is useful for treating agitation. [Solution] The present inventors conducted intensive studies to provide a therapeutic agent for agitation. As a result, they found that 4-{...  
WO/2018/116107A1
Provided are IDO inhibitor compounds of Formula (I) and pharmaceutically acceptable salts thereof, their pharmaceutical compositions, their methods of preparation, and methods for their use in the prevention and/or treatment of diseases ...  
WO/2018/118736A1
The present invention is directed to 6,5-fused heteroarylpiperidine ether compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described he...  
WO/2018/109649A1
The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to compounds of Formula (I), and...  
WO/2018/108695A1
The present invention relates to phenyltriazolinones of formula (I) (I), or their agriculturally acceptable salts or derivatives,wherein the variables are defined according to the description, processes and intermediates for preparing th...  
WO/2018/106646A1
The invention relates to triazole compounds of formula (I') or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: wherein A is selected from the group consisting of (i), (ii), (iii), (iv), (v), and...  
WO/2018/103757A1
Provided is a CCR2/CCR5 receptor antagonist and the use thereof in the preparation of a drug for treating diseases associated with the CCR2/CCR5. In particular, disclosed are a compound represented by formula (I) and a pharmaceutically a...  
WO/2018/099416A1
Provided in the present invention are an azo-compound, a polymer and a preparation method and a use. The structural formula of the azo-compound is shown in formula (I), wherein R1、R2、R3 and m have meanings as described in the descrip...  
WO/2018/098207A1
Provided herein are dUTPase inhibitors, compositions comprising such compounds and methods of using such compounds and compositions.  
WO/2018/093579A1
Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions...  
WO/2018/089402A1
There are described RORγ Gamma modulators of the formula (I), (I) or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutic...  
WO/2018/087019A1
The invention relates to a method for producing amide bonds, particularly peptide bonds, with the aid of new amide coupling reagents containing an anion of formula (I); the invention also relates to these new reagents and to the producti...  
WO/2018/085932A1
The present invention provides novel crystalline forms of Lesinurad, pharmaceutical compositions comprising these crystalline forms, and their use in the treatment of hyperuricemia associated with gout. Specific crystalline forms provide...  
WO/2018/077923A1
The present invention provides triazolone compounds compounds of general formula (I) : in which R1, R2, R3, R4 and R5 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds,...  

Matches 1 - 50 out of 10,798